0 13 Transcription Transcription NNP 14 20 factor factor NN 21 27 GATA-3 gata-3 NN 28 30 is be VBZ 31 45 differentially differentially RB 46 55 expressed express VBN 56 58 in in IN 59 65 murine murine JJ 66 69 Th1 th1 NN 70 73 and and CC 74 77 Th2 th2 NN 78 83 cells cell NNS 84 87 and and CC 88 96 controls control VBZ 97 109 Th2-specific th2-specific JJ 110 120 expression expression NN 121 123 of of IN 124 127 the the DT 128 141 interleukin-5 interleukin-5 NN 142 146 gene gene NN 146 147 . . . 149 162 Interleukin-5 Interleukin-5 NNP 163 164 ( ( ( 164 168 IL-5 IL-5 NNP 168 169 ) ) ) 169 170 , , , 171 176 which which WDT 177 179 is be VBZ 180 188 produced produce VBN 189 191 by by IN 192 198 CD4(+) cd4(+) JJ 199 200 T t NN 201 207 helper helper NN 208 209 2 2 CD 210 211 ( ( ( 211 214 Th2 th2 NN 214 215 ) ) ) 216 221 cells cell NNS 221 222 , , , 223 226 but but CC 227 230 not not RB 231 233 by by IN 234 237 Th1 th1 NN 238 243 cells cell NNS 243 244 , , , 245 250 plays play VBZ 251 252 a a DT 253 256 key key JJ 257 261 role role NN 262 264 in in IN 265 268 the the DT 269 280 development development NN 281 283 of of IN 284 296 eosinophilia eosinophilia NN 297 299 in in IN 300 306 asthma asthma NN 306 307 . . . 308 315 Despite despite IN 316 326 increasing increase VBG 327 335 evidence evidence NN 336 340 that that IN 341 344 the the DT 345 352 outcome outcome NN 353 355 of of IN 356 360 many many JJ 361 369 diseases disease NNS 370 372 is be VBZ 373 383 determined determine VBN 384 386 by by IN 387 390 the the DT 391 396 ratio ratio NN 397 399 of of IN 400 403 the the DT 404 407 two two CD 408 415 subsets subset NNS 416 418 of of IN 419 425 CD4(+) cd4(+) JJ 426 427 T t NN 428 434 helper helper NN 435 440 cells cell NNS 440 441 , , , 442 445 Th1 Th1 NNP 446 449 and and CC 450 453 Th2 Th2 NNP 453 454 , , , 455 458 the the DT 459 468 molecular molecular JJ 469 474 basis basis NN 475 478 for for IN 479 483 Th1- Th1- NNP 484 487 and and CC 488 492 Th2- th2- NN 493 501 specific specific JJ 502 506 gene gene NN 507 517 expression expression NN 518 525 remains remain VBZ 526 528 to to TO 529 531 be be VB 532 542 elucidated elucidate VBN 542 543 . . . 544 546 We we PRP 547 557 previously previously RB 558 569 established establish VBD 570 571 a a DT 572 580 critical critical JJ 581 585 role role NN 586 589 for for IN 590 593 the the DT 594 607 transcription transcription NN 608 614 factor factor NN 615 621 GATA-3 gata-3 NN 622 624 in in IN 625 629 IL-5 IL-5 NNP 630 638 promoter promoter NN 639 649 activation activation NN 650 652 in in IN 653 657 EL-4 el-4 NN 658 663 cells cell NNS 663 664 , , , 665 670 which which WDT 671 678 express express VBP 679 683 both both CC 684 688 Th1- th1- NN 689 692 and and CC 693 701 Th2-type th2-type JJ 702 711 cytokines cytokine NNS 711 712 . . . 713 716 Our our PRP$ 717 724 studies study NNS 725 733 reported report VBN 734 738 here here RB 739 750 demonstrate demonstrate VBP 751 755 that that IN 756 762 GATA-3 gata-3 NN 763 765 is be VBZ 766 774 critical critical JJ 775 778 for for IN 779 789 expression expression NN 790 792 of of IN 793 796 the the DT 797 801 IL-5 il-5 NN 802 806 gene gene NN 807 809 in in IN 810 814 bona bona FW 815 819 fide fide FW 820 823 Th2 th2 NN 824 829 cells cell NNS 829 830 . . . 831 838 Whereas whereas IN 839 848 mutations mutation NNS 849 851 in in IN 852 855 the the DT 856 862 GATA-3 gata-3 NN 863 867 site site NN 868 877 abolished abolish VBD 878 886 antigen- antigen- NN 887 889 or or CC 890 895 cAMP- camp- NN 896 906 stimulated stimulate VBD 907 911 IL-5 il-5 NN 912 920 promoter promoter NN 921 931 activation activation NN 932 934 in in IN 935 938 Th2 th2 NN 939 944 cells cell NNS 944 945 , , , 946 953 ectopic ectopic JJ 954 964 expression expression NN 965 967 of of IN 968 974 GATA-3 gata-3 NN 975 977 in in IN 978 981 Th1 th1 NN 982 987 cells cell NNS 988 990 or or CC 991 993 in in IN 994 995 a a DT 996 1008 non-lymphoid non-lymphoid JJ 1008 1009 , , , 1010 1028 non-IL-5-producing non-il-5-producing JJ 1029 1033 cell cell NN 1034 1038 line line NN 1039 1048 activated activate VBD 1049 1052 the the DT 1053 1057 IL-5 il-5 NN 1058 1066 promoter promoter NN 1066 1067 . . . 1068 1074 During during IN 1075 1078 the the DT 1079 1094 differentiation differentiation NN 1095 1097 of of IN 1098 1103 naive naive JJ 1104 1110 CD4(+) cd4(+) JJ 1111 1112 T t NN 1113 1118 cells cell NNS 1119 1127 isolated isolate VBN 1128 1132 from from IN 1133 1134 T t NN 1135 1139 cell cell NN 1140 1148 receptor receptor NN 1149 1159 transgenic transgenic JJ 1160 1164 mice mouse NNS 1164 1165 , , , 1166 1172 GATA-3 gata-3 NN 1173 1177 gene gene NN 1178 1188 expression expression NN 1189 1192 was be VBD 1193 1205 up-regulated up-regulate VBN 1206 1208 in in IN 1209 1219 developing develop VBG 1220 1223 Th2 th2 NN 1224 1229 cells cell NNS 1229 1230 , , , 1231 1234 but but CC 1235 1238 was be VBD 1239 1253 down-regulated down-regulate VBN 1254 1256 in in IN 1257 1260 Th1 th1 NN 1261 1266 cells cell NNS 1266 1267 , , , 1268 1271 and and CC 1272 1280 antigen- antigen- NN 1281 1283 or or CC 1284 1298 cAMP-activated camp-activated JJ 1299 1302 Th2 th2 NN 1303 1308 cells cell NNS 1309 1310 ( ( ( 1310 1313 but but CC 1314 1317 not not RB 1318 1321 Th1 th1 NN 1322 1327 cells cell NNS 1327 1328 ) ) ) 1329 1338 expressed express VBD 1339 1342 the the DT 1343 1349 GATA-3 gata-3 NN 1350 1357 protein protein NN 1357 1358 . . . 1359 1363 Thus thus RB 1363 1364 , , , 1365 1371 GATA-3 GATA-3 NNP 1372 1375 may may MD 1376 1380 play play VB 1381 1383 an an DT 1384 1393 important important JJ 1394 1398 role role NN 1399 1401 in in IN 1402 1405 the the DT 1406 1413 balance balance NN 1414 1421 between between IN 1422 1425 Th1 th1 NN 1426 1429 and and CC 1430 1433 Th2 th2 NN 1434 1441 subsets subset NNS 1442 1444 in in IN 1445 1451 immune immune JJ 1452 1461 responses response NNS 1461 1462 . . . 1463 1473 Inhibition Inhibition NNP 1474 1476 of of IN 1477 1483 GATA-3 GATA-3 NNP 1484 1492 activity activity NN 1493 1496 has have VBZ 1497 1508 therapeutic therapeutic JJ 1509 1518 potential potential NN 1519 1521 in in IN 1522 1525 the the DT 1526 1535 treatment treatment NN 1536 1538 of of IN 1539 1545 asthma asthma NN 1546 1549 and and CC 1550 1555 other other JJ 1556 1573 hypereosinophilic hypereosinophilic JJ 1574 1582 diseases disease NNS 1582 1583 . . .